• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To register, simply click the Register button at the top right.

Commentary: COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines


Senior Member
Author: Uri Galili, Department of Medicine, Rush Medical College, Chicago, IL, USA
Published: July 25, 2021
PMID: 34304693
doi: 10.1080/21505594.2021.1939924

The use of gene-based Covid-19 vaccines containing the S protein gene has proven to be very effective in protection against infection by SARS-CoV-2. However, increasing numbers of variants with higher transmissibility and/or virulence have been reported. These variants raise concerns that immunization with gene-based vaccines containing only the S protein gene may allow for emergence of more virulent mutated variants by a Darwinian-like “natural-selection” process. Such variants may evade protective anti-S protein antibodies in immunized individuals. A concrete example for a virus acquiring mutations that facilitate immune evasion in humans (called “escape-mutations”) is that of HIV within infected patients. These mutations increase the number of N (asparagine)-linked carbohydrate chains (N-glycans) forming the “glycan-shield” on gp120 of HIV. Gp120 is the envelope glycoprotein that mediates HIV infection of host-cells, analogous to the role of S protein in SARS-CoV-2. The glycan-shield on gp120 masks many antigenic epitopes on this glycoprotein and the additional glycans on mutated HIV variants prevent binding of neutralizing-antibodies. The S protein of SARS-CoV-2 has a glycan-shield of 22 N-glycans, covering ~65% of its surface and thus masking various antigenic peptides from detection by host immune systems. N-glycans are synthesized on asparagine (Asn) within the Asn-X-Ser/Thr (N-X-S/T) sequon, where X is any amino acid other than proline. Thus, any substitution mutation that introduces Asn or Ser/Thr to form this sequon will result in synthesis of additional N-glycans that can further mask regions of the S protein recognized by neutralizing antibodies.